the Paoli-Calmettes Institute in France and the Shanghai Cancer Institute in China entered the list for the first time. As always, oncology deals continue to dominate the landscape. CRADA to develop a connexin-based peptide therapeutic, ACT1, as a topical ophthalmic therapy for diabetic keratopathy and persistent corneal defects.
National Institutes of Health (NIH), GlaxoSmithKline
Partnership to develop one or more broadly neutralizing monoclonal antibodies against HIV infection.
NIH, Wyeth Nutrition
Five-year partnership called the 'Baby Connectome Project' studying brains of healthy children up to 5 years old.
NIH, GenVec
Collaboration using GenVec's gorilla adenovirus vectors of low human seroprevalence to deliver antigens for a variety of malaria vaccine candidates.
NIH, others
Partners in an 'Alzheimer's Big Data' portal for use by the research community.
NIH, University of Massachusetts Medical School and Scripps, Padlock
Collaboration to determine the role of individual peptidylarginine deiminase (PAD) enzymes in certain animal disease models and to evaluate PAD inhibitors in enzymatic assays, animal models and human cellular systems. Genocea Biosciences Collaboration to screen T-cell responses of melanoma and non-small-cell lung cancer patients treated with checkpoint inhibitors against patient-specific putative neoantigens.
Cesca Therapeutics Partnership to use Cesca's CellWerks portfolio of devices for intralaboratory stem cell purification applications.
Illumina
Collaboration on noninvasive cancer diagnosis and monitoring.
Peregrine Pharmaceuticals Collaboration on combinations of phosphatidyl serine-targeting agents, including bavituximab, with other immune modulators.
Multiple Myeloma Research Foundation (3 deals)
Inflection Biosciences Preclinical testing of Inflection's dual-mechanism phosphatidyl inositol mannoside/phosphatidyl inositol 3-kinase inhibitor, IBL-202.
GNS Healthcare
Initiative to deploy predictive big data analytics on patient data from CoMMpass Study in multiple myeloma.
Adaptive, Onyx Collaboration to perform sequencing-based assessment of minimal residual disease on multiple myeloma patients over 5 years.
Cold Spring Harbor (2 deals) Hairpin Technologies Initiative to expand the commercial distribution and research use of short hairpin RNA technology.
GlaxoSmithKline
Collaboration with GSK on obesity and type 2 diabetes.
Cleveland Clinic (2 deals) Human Longevity Collaboration to apply whole-genome, cancer and microbiome sequencing to heart disease.
Procter & Gamble Cleveland HeartLab to collaborate on a diagnostic and management solution for a heart disease biomarker discovered by the Cleveland Clinic.
Paoli-Calmettes Institute (2 deals)
Innate Pharma Initiative to conduct translational research aimed at hematological cancers and at identifying associated biomarkers.
Eisai
Collaboration to study protein-protein inhibitors for oncology indications. T h e T e c h n io n I n s t it u t e T h e R o c k e f e ll e r U n iv e r s it y S h a n g h a i C a n c e r I n s t it u t e S a n f o r d -B u r n h a m P a o li -C a lm e t t e s I n s t it u t e 
